SCLC

Anlotinib improves overall survival in relapsed SCLC

“The results of ALTER 1202 are incredible, not just for the survival benefit they reveal for anlotinib third-line in small-cell lung cancer (SCLC), but also for the magnitude of this benefit,” says Professor Sanjay Popat…

Read More